OSE IMMUNO (OSE.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:OSE - FR0012127173 - Common Stock
OSE.PA Key Statistics, Chart & Performance
The current stock price of OSE.PA is 4.98 EUR. In the past month the price increased by 4.18%. In the past year, price decreased by -26.22%.
OSE.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 65.04 | 42.77B | ||
| ARGX.BR | ARGENX SE | 64.94 | 42.70B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.72B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.71B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.64B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.88B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.87B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 856.31M | ||
| IVA.PA | INVENTIVA SA | N/A | 782.22M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20 | 666.67M |
Related stock screener links
About OSE.PA
Company Profile
OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. The company is headquartered in Nantes, Pays De La Loire and currently employs 68 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
Company Info
OSE IMMUNO
22, boulevard Benoni Goullin
Nantes PAYS DE LA LOIRE FR
Employees: 52
Phone: 33228291010
OSE IMMUNO / OSE.PA FAQ
What does OSE do?
OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. The company is headquartered in Nantes, Pays De La Loire and currently employs 68 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
What is the stock price of OSE IMMUNO today?
The current stock price of OSE.PA is 4.98 EUR. The price decreased by -0.8% in the last trading session.
Does OSE stock pay dividends?
OSE.PA does not pay a dividend.
What is the ChartMill rating of OSE IMMUNO stock?
OSE.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of OSE IMMUNO (OSE.PA) based on its PE ratio?
OSE IMMUNO (OSE.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.59).
Can you provide the market cap for OSE IMMUNO?
OSE IMMUNO (OSE.PA) has a market capitalization of 111.85M EUR. This makes OSE.PA a Micro Cap stock.
What is the next earnings date for OSE stock?
OSE IMMUNO (OSE.PA) will report earnings on 2026-03-24, after the market close.
OSE.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OSE.PA. When comparing the yearly performance of all stocks, OSE.PA is a bad performer in the overall market: 93.8% of all stocks are doing better.
OSE.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OSE.PA. While OSE.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
OSE.PA Financial Highlights
Over the last trailing twelve months OSE.PA reported a non-GAAP Earnings per Share(EPS) of -1.59. The EPS decreased by -191.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.44% | ||
| ROE | -68.84% | ||
| Debt/Equity | 0.64 |
OSE.PA Forecast & Estimates
7 analysts have analysed OSE.PA and the average price target is 15.61 EUR. This implies a price increase of 213.37% is expected in the next year compared to the current price of 4.98.
For the next year, analysts expect an EPS growth of -98.83% and a revenue growth -42.08% for OSE.PA